Komatsu S, Grisham M B, Russell J M, Granger D N
Department of Physiology, LSU Medical Center, Shreveport 71130-3932, USA.
Gut. 1997 Nov;41(5):636-41. doi: 10.1136/gut.41.5.636.
Recent reports have described a modulating influence of nitric oxide (NO) on intestinal mucosal permeability and have implicated a role for mast cells in this NO mediated process.
To assess further the contribution of mast cells to the mucosal permeability changes elicited by the NO synthase (NOS) inhibitor NG-nitro-L-arginine methylester (L-NAME), using mast cell deficient (W/Wv) and mast cell replete mice (+/+).
Chromium-51 EDTA clearance (from blood to jejunal lumen), jejunal NOS and myeloperoxidase (MPO) activities, and plasma nitrate/nitrite levels were monitored.
The increased EDTA clearance elicited by intraluminal L-NAME in W/Wv mice (4.4-fold) was significantly greater than the response observed in control (+/+) mice (1.8-fold). The exacerbated response in W/Wv mice was greatly attenuated by pretreatment with either dexamethasone (1.3-fold) or the selective inducible NOS inhibitor, aminoguanidine (1.4-fold), and partially attenuated by the mast cell stabiliser, lodoxamide (2.9-fold). Jejunal inducible NOS activity was significantly higher in W/Wv than in +/+ mice, while jejunal MPO was lower in W/Wv mice than in +/+ mice, suggesting that the higher inducible NOS in W/Wv does not result from the recruitment of inflammatory cells into the gut. The higher inducible NOS activity in the jejunum of W/Wv was significantly reduced by dexamethasone treatment.
Our results suggest that mast cells normally serve to inhibit inducible NOS activity tonically in the gut and that inhibitors of NOS elicit a larger permeability response when this tonic inhibitory influence is released by mast cell depletion.
最近的报告描述了一氧化氮(NO)对肠黏膜通透性的调节作用,并表明肥大细胞在这一由NO介导的过程中发挥作用。
使用肥大细胞缺陷(W/Wv)小鼠和肥大细胞充足(+/+)小鼠,进一步评估肥大细胞对一氧化氮合酶(NOS)抑制剂N-硝基-L-精氨酸甲酯(L-NAME)引起的黏膜通透性变化的作用。
监测铬-51乙二胺四乙酸(EDTA)清除率(从血液到空肠肠腔)、空肠NOS和髓过氧化物酶(MPO)活性以及血浆硝酸盐/亚硝酸盐水平。
W/Wv小鼠肠腔内L-NAME引起的EDTA清除率增加(4.4倍)显著大于对照(+/+)小鼠(1.8倍)。W/Wv小鼠中这种加剧的反应通过地塞米松预处理(1.3倍)或选择性诱导型NOS抑制剂氨基胍(1.4倍)得到极大减弱,而肥大细胞稳定剂洛度沙胺预处理(2.9倍)使其部分减弱。W/Wv小鼠空肠诱导型NOS活性显著高于+/+小鼠,而W/Wv小鼠空肠MPO低于+/+小鼠,这表明W/Wv小鼠中较高的诱导型NOS并非由炎症细胞向肠道募集所致。地塞米松治疗显著降低了W/Wv小鼠空肠中较高的诱导型NOS活性。
我们的结果表明,肥大细胞通常在肠道中发挥持续抑制诱导型NOS活性的作用,当肥大细胞耗竭释放这种持续的抑制作用时,NOS抑制剂会引发更大的通透性反应。